Loading
A phase 3 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, not yet recruiting.
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC is a phase 3 interventional study registered as NCT07720193 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2026-11-16. Conditions recorded: Advanced Extrapulmonary Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide injection, Cisplatin injection, Carboplatin injection and LBL-024 placebo for injection.
Shares Opamtistomig, Nanjing Leads Biolabs, Neuroendocrine tumours and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/